Livdelzi Patient Assistance Program

(seladelpar lysine)

Key Takeaways

  1. Livdelzi® (seladelpar lysine) is an oral prescription medication approved to treat primary biliary cholangitis (PBC) in adults.
  2. Livdelzi is a PPAR-δ agonist that helps regulate bile acid metabolism and reduce inflammation associated with primary biliary cholangitis.
  3. Livdelzi may be used with ursodeoxycholic acid (UDCA) in patients who have not responded adequately to UDCA or alone in patients who cannot tolerate UDCA.
  4. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Livdelzi more affordable.

 

Introduction

Primary biliary cholangitis (PBC) is a rare, chronic autoimmune liver disease that gradually damages the small bile ducts within the liver. Over time, this damage can lead to inflammation, scarring, and impaired liver function. Although ursodeoxycholic acid (UDCA) is the standard first-line treatment, some patients do not respond adequately or cannot tolerate the medication.

Livdelzi is an oral prescription medication approved for adults with primary biliary cholangitis. It may be used in combination with UDCA for patients who have had an inadequate response to treatment or as monotherapy for those who cannot tolerate UDCA. By targeting pathways involved in bile acid metabolism and liver inflammation, Livdelzi helps improve important laboratory markers associated with PBC.

Prescription Hope offers qualified patients access to affordable medications such as Livdelzi through patient assistance programs.

What Is the Livdelzi Patient Assistance Program?

Understanding Prescription Assistance Programs

With the high cost of specialty medications, patients often search for Livdelzi prescription assistance or medication savings programs.

Manufacturers understand that patients searching for these and similar medications need financial relief for their medication costs. As a result, many manufacturers offer patient assistance programs to help qualified patients.

These programs provide affordable medications to qualified patients. Unfortunately, these programs can be difficult to navigate, leaving patients frustrated when applying on their own.

How Expert Advocates Help Make Livdelzi More Affordable

Personalized Medication Assistance

Patients looking for trusted prescription assistance need look no further than Prescription Hope. Our patient support services handle the the patient assistance application process from start to finish.

We manage form completion, document and signature collection, coordination with healthcare providers and manufacturers, and all the administrative tasks that come with patient assistance programs.

Ongoing Patient Support

At Prescription Hope, we don’t just provide application assistance services, but we also offer long-term medication assistance. Our team manages administrative tasks such as form and document updates, issue resolution, program monitoring, yearly renewals, and even refill scheduling.

Livdelzi Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$12,321.44

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Primary Biliary Cholangitis Treatment Costs

While medication costs for Primary Biliary Cholangitis treatment can be expensive, Livdelzi cost assistance through Prescription Hope can make a world of difference.

For $70.00 per month, per medication, qualified patients get access to specialty Primary Biliary Cholangitis medication assistance without any hidden fees or charges, medication costs, or variable pricing systems.

Livdelzi Patient Assistance Eligibility

General Eligibility Requirements

While determining specific eligibility requirements for Livdelzi patient assistance is best done by enrolling with Prescription Hope, it is also helpful to understand general eligibility requirements.

These requirements include:

Income: Each program maintains its own income thresholds.

Insurance: Each program maintains its own requirement regarding insurance coverage status.

Prescription: All qualified patients must have a valid prescription for their brand-name medication for which they wish to apply.

U.S. Residency: All qualified patients must have legal U.S. residency.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Patients who wish to enroll in Livdelzi assistance can do so today from the comfort of their own home by enrolling with Prescription Hope. It takes only 6 simple steps:

  1. Submit Information: Our online form is straightforward and can be completed in a few minutes.
  2. Advocate Contact: A patient advocate will contact you in 1-2 business days.
  3. Document Collection: Following a quick prequalification, our team will collect needed documents.
  4. Provider Coordination: We connect with your healthcare provider to secure vital signatures.
  5. Program Submission: Our team completes your application, submits it, and continues to follow up with the manufacturer.
  6. Medication Delivery: Once approved, qualified patients can typically expect to receive their medication within 1-2 weeks, though shipping times may vary. All medication shipments come directly from the manufacturer to your home or doctor’s office.

Understanding Livdelzi

How Livdelzi Works

Livdelzi activates peroxisome proliferator-activated receptor delta (PPAR-δ), a protein that helps regulate inflammation, bile acid metabolism, and liver cell function.

By activating this receptor, Livdelzi helps reduce cholestatic inflammation and improve bile acid homeostasis, leading to lower levels of liver enzymes associated with primary biliary cholangitis. While it improves important biochemical markers of liver disease, it has not yet been proven to improve survival or prevent liver failure.

What Conditions Does Livdelzi Treat?

Livdelzi is FDA-approved for the treatment of primary biliary cholangitis (PBC) in adults:

  • In combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA
  • As monotherapy in adults who are unable to tolerate UDCA

This indication was granted under the FDA’s Accelerated Approval pathway based on improvements in alkaline phosphatase (ALP), a marker of liver disease. Continued approval may depend on verification and description of long-term clinical benefit in confirmatory trials.

Livdelzi is not recommended for patients with decompensated cirrhosis.

Benefits of Treatment

For appropriate patients with primary biliary cholangitis, Livdelzi may:

  • Lower alkaline phosphatase (ALP) levels
  • Improve other liver function markers, including bilirubin in some patients
  • Improve biochemical markers associated with disease activity
  • Offer an additional treatment option when UDCA alone is not effective
  • Provide an alternative for patients who cannot tolerate UDCA

Because FDA approval was based on surrogate laboratory markers, long-term clinical outcomes continue to be evaluated.

Important Safety Information and Side Effects

This medication does not carry an FDA Boxed Warning.

The most commonly reported side effects include:

  • Headache
  • Abdominal pain
  • Nausea
  • Abdominal bloating
  • Diarrhea
  • Dizziness
  • Weight gain

Laboratory abnormalities may include:

  • Increased liver enzyme levels
  • Increased creatine phosphokinase (CPK)

Patients should discuss the following risks with their healthcare provider before and during treatment:

  • Drug-induced liver injury (DILI), including elevations in liver tests that may require treatment interruption or discontinuation
  • Liver injury or worsening liver function
  • Gallbladder- or bile duct-related complications
  • Use is not recommended in patients with decompensated cirrhosis.
  • Possible muscle injury with elevated creatine phosphokinase (CPK)
  • Need for routine liver function monitoring during treatment.

There are no adequate human data available to establish a drug-associated risk during pregnancy. Patients who are pregnant or planning to become pregnant should discuss the potential risks and benefits of treatment with their healthcare provider.

It is unknown whether seladelpar passes into human breast milk. Patients should discuss the benefits of breastfeeding and the potential risks of treatment with their healthcare provider before starting Livdelzi.

Livdelzi may interact with:

  • Bile acid sequestrants (Livdelzi should be administered at least 4 hours before or after these medications)
  • Organic anion transporting polypeptide (OATP) inhibitors
  • Other medications that may affect liver function or increase the risk of hepatotoxicity

Patients should inform their healthcare provider about all prescription medications, over-the-counter medicines, vitamins, and herbal supplements before beginning treatment.

Livdelzi is taken orally as a 10 mg capsule once daily and may be taken with or without food. Capsules should be swallowed whole. Depending on the patient’s treatment plan, Livdelzi may be used alone or together with UDCA. Patients taking a bile acid sequestrant should separate doses by at least 4 hours. Treatment is typically prescribed and monitored by hepatologists or gastroenterologists experienced in treating chronic liver disease.

Access to Multiple Medications

Support Beyond Just One Brand-name Medication

Are you looking for primary biliary cholangitis medication support as well as other specialty medication access? Prescription Hope routinely helps qualified patients access multiple medication assistance programs at once. Whether one or many, our dedicated team provides all services for a simple $70.00 per medication, per month.

Why Choose Prescription Hope

Patient-Focused Medication Support

For two decades, patients have trusted Prescription Hope to help them receive patient-centered assistance and support that provides them with prescription affordability support. Our Florida-based access specialists can provide Livdelzi assistance through Prescription Hope.

Simplified Access to Prescription Medications

Our patient assistance services help provide access to primary biliary cholangitis medication and the support needed to help qualified patients lower their medication costs and have peace of mind when it comes to prescription medication prices.

Ongoing Prescription Assistance

Prescription Hope not only helps with primary biliary cholangitis treatment support, but we also provide long-term medication support. Our dedicated team of patient advocates takes care of form updates, issue resolution, yearly renewals, program monitoring, and even refill scheduling.

If you need access to affordable brand-name medications like Livdelzi, then enroll with Prescription Hope today!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!